Working Groups

Latest News

Flu Survey: IPC Working ...

Please take the IPC Working Group survey on influenza.

Read More
ISAC Funded Study

Results of a study sponsored by ISAC have been published in JAMA.

Read More

Membership

Current Officers

Chair

Kordo Saaed

Kordo.saeed@hhft.nhs.uk

Secretary

Peter Laszlo Kanizsai

plkanizsai@yahoo.com

All Members

Albertus Beishuizen (the Netherlands)
Mike Broyles (USA)
Ricard Ferrer (Spain)
Gaëtan Gavazzi (France)
Eric Howard Gluck (USA)
Jens Ulrik Stæhr Jensen (Denmark)
Andrea Kwa (Singapore)
Charles-Edouard Luyt (France)
Michael Oppert (Germany)
Mario Plebani (Italy)
Philipp Schütz (Switzerland)
Sergey Shlyapnikov (Russian Federation)
Giulio Toccafondi (Italy)
Jennifer Townsend (USA)
Tobias Welte (Germany)

How to Join

Members of an ISAC Member Society are eligible to join any of our Working Groups. If you are a member and would like to join this group, please contact the Chairperson and Secretary (if applicable).

Aims and Objectives

Given the amount of research and investment in the field of novel diagnostics and biomarkers, it is predicted that provision of medicine in the future will be transformed. The main aims of novel diagnostics and biomarkers are not only to recognise infection and/or sepsis, but also to assist in triaging patients with regards to avoiding admission, ward admission, intensive care admission and even prognosis and predicting outcome.

 

Another aspect of novel diagnostics and biomarkers is to improve antibiotic stewardship in clinical settings. Therefore, this working group aims to:

 

  • Organise educational meetings and provide educational material on the application of novel diagnostics and biomarkers in clinical practice e.g. antibiotic stewardship and/or triaging.
  • Promote a “network” to collect data from those centres that use novel diagnostics and/or biomarkers and audits of good practice with regards to novel diagnostics and biomarkers.
  • Develop practice guidelines or recommendations for a correct approach in applying these novel technologies and biomarkers in clinical practice.

We hope that the group’s work will result in a closer collaboration among international experts who can bridge the gap between studies, clinical applications and patients’ needs, thereby improving not only antibiotic stewardship and better quality of patient care, but also in reducing the cost to healthcare systems across the world.

Last updated: November 15th-2018